ARA-290 (Cibinetide): A Closer Look at the Small Fiber Neuropathy Research

What is ARA-290?

ARA-290, also known as cibinetide, is a small synthetic peptide that grew out of research into erythropoietin (EPO), the hormone best known for stimulating red blood cell production. Scientists noticed that EPO also carries a separate, tissue-protective signal, and they set out to isolate that repair-related activity from the blood-building effect. ARA-290 is the result: a short peptide designed to engage tissue-protective signaling without raising red blood cell counts.

This matters because it places ARA-290 in a more specific niche than a general 'recovery' compound. It is being explored as a way to support nerve and tissue repair through a defined biological pathway, and most of its human research has centered on one particular problem: small fiber neuropathy, a form of nerve damage that affects the tiny fibers responsible for pain and sensation.

How it is thought to work

ARA-290 is understood to act on what researchers call the innate repair receptor, a signaling complex involved in protecting tissue and calming local inflammation after injury. By engaging this pathway, the peptide is proposed to support the survival and regeneration of small nerve fibers and to dampen the inflammatory environment that can accompany nerve damage.

It is important to be clear about the limits of this picture. Much of the receptor-level detail comes from laboratory and mechanistic research, and a plausible mechanism is not the same as a proven clinical effect. What makes ARA-290 more interesting than many peptides is that the mechanism has been paired with actual controlled human testing, which is where the evidence below becomes relevant.

What the research shows

The human evidence for ARA-290 is unusually concrete for a peptide of this kind, though it is still early and narrow. A 2012 randomized, double-blind pilot trial in sarcoidosis patients with small fiber neuropathy reported that ARA-290 was safe and was associated with improved neuropathic symptoms. This was a small study, but it was placebo-controlled, which gives its signal more weight than open-label or anecdotal reports.

A 2013 randomized controlled trial built on this, again in sarcoidosis-associated small nerve fiber loss. It replicated the symptom benefit and, importantly, added an objective measure: an increase in corneal nerve fiber density, meaning the trial documented a physical change in nerve fibers rather than relying on symptom reports alone. A larger 2017 multicentre randomized controlled trial, published in an ophthalmology journal, focused specifically on this objective endpoint and reported that cibinetide improved corneal nerve fiber abundance in the same patient population.

Taken together, these are genuine randomized human trials with both subjective and objective endpoints, which is more than can be said for many compounds in this space. But the honest framing is equally important: all three studies were in one condition, small fiber neuropathy in sarcoidosis, and ranged from small pilots to a multicentre trial rather than large definitive studies. ARA-290 has not been established as a broad treatment across many conditions, and it remains investigational.

What it is being explored for and who it may suit

Based on the existing evidence, ARA-290 is most directly relevant to research interest in small fiber neuropathy and nerve regeneration, where the controlled trials have shown both symptom and structural signals. Its tissue-protective mechanism has prompted wider scientific curiosity, but it would be misleading to extend the human findings beyond the neuropathy work that has actually been done.

Because ARA-290 is investigational and not an approved medicine in all jurisdictions, it is not something to approach casually or on one's own. Whether it is appropriate for a given person depends on their specific situation, diagnosis, and goals, which is a conversation for a qualified physician rather than a decision to make from an article.

How Strong Craft Regen approaches ARA-290

Strong Craft Regen is a coordination and education service, not a clinic and not a prescriber. We help people understand what the research does and does not say, and we coordinate care that is delivered by licensed physicians at Innovita Clinic in Vilnius, Lithuania. With a peptide like ARA-290, where the human evidence is real but early and confined to specific contexts, that physician oversight is not a formality. It is the point.

If you are curious about ARA-290 and want to understand how it fits within proper medical evaluation, the next step is a conversation, not a purchase. You can book a call with us to talk through your situation and what evidence-based, physician-supervised coordination would look like. This article is educational and is not medical advice or a treatment recommendation.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. ARA-290 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.